Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429911 | 0.82 | GHSR (0.70) | GHSRADRB3EPHX1ALDH1A1HTT | |
| SCHEMBL6074095 | 0.81 | GHSR (0.67) | GHSRADRB3ADRB1ADRB2 | |
| SCHEMBL6987941 | 0.79 | EPHX1 (0.54) | GHSREPHX1ALDH1A1HTTEPHX2 | |
| SCHEMBL6438783 | 0.78 | EPHX1 (0.84) | GHSREPHX1ALDH1A1HTTEPHX2 | |
| SCHEMBL11033138 | 0.78 | EPHX1 (0.84) | GHSREPHX1ALDH1A1HTTEPHX2 | |
| SCHEMBL11034317 | 0.78 | EPHX1 (0.84) | GHSREPHX1ALDH1A1HTTEPHX2 | |
| SCHEMBL8788507 | 0.77 | CA2 (0.70) | GHSRADRB3EPHX1ALDH1A1HTT | |
| SCHEMBL6074124 | 0.77 | GHSR (0.67) | GHSRADRB3EPHX1ALDH1A1HTT | |
| SCHEMBL7095018 | 0.77 | GHSR (0.67) | GHSRADRB3EPHX1ALDH1A1HTT | |
| SCHEMBL12386393 | 0.77 | KMT2A (0.72) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | WYETH (US) | 2003-02-06 | — | — | US | disclosed |
| US-6498170-B2 | 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006221-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | GHSR 99/4885ADRB3 1/4885ADRB1 2/4885 |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | GHSR 87/4885ADRB3 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.